about
Incorporation of the time aspect into the liability-threshold model for case-control-family data.Association of physical function with predialysis blood pressure in patients on hemodialysisDiminished white matter injury over time in a cohort of premature newborns.Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.Crude incidence in two-phase designs in the presence of competing risks.Association of Performance-Based and Self-Reported Function-Based Definitions of Frailty with Mortality among Patients Receiving Hemodialysis.Height at First RRT and Mortality in ChildrenContemporary Profile of Seizures in Neonates: A Prospective Cohort StudyDifferences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China.HIV prevention trial design in an era of effective pre-exposure prophylaxis.HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis.Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey.Perceived Social Norms About Oral PrEP Use: Differences Between African-American, Latino and White Gay, Bisexual and Other Men Who Have Sex with Men in Texas.Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis.Quantitative evaluation of an innovation contest to enhance a sexual health campaign in ChinaInterim monitoring in a treatment strategy trial with a composite primary endpointEvaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factorsTesting a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled TrialDevelopment and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settingsThe value of kinetic glomerular filtration rate estimation on medication dosing in acute kidney injuryHIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular healthImpact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration ProjectRetention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: Regionally representative estimates using a multistage-sampling-based approachExercise Improves Self-Reported Sexual Function Among Physically Active AdultsCorrection: Retention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: Regionally representative estimates using a multistage-sampling-based approachAdvancing Novel PrEP Products - Alternatives to Non-InferiorityRisk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort
P50
Q31156215-AD08CE89-EEB4-434B-8DA9-C93268AE6A95Q34587194-84AD55F5-93E9-4EB5-8114-FC5D87965F88Q34758677-65AFE976-D0D3-4546-912C-1FD831E1450CQ35473669-93F48F17-8DB3-4BD0-924C-6CDA3BCF13DBQ35891186-27C73101-A3F3-448F-846F-AB0A99903855Q36770837-038846AC-C4EC-4A09-8022-B258FC28E08BQ36874546-1189057C-071B-4863-9AA7-D8729252118AQ37047857-AA6199A2-F1F6-47C1-B9C1-E612386AC2B7Q38851078-B125A9B4-EAFC-4AB7-A577-FB22D9535616Q40135129-3FD09215-5C83-41A4-8AE5-A9B6F29D97C8Q45961960-A37625C6-0E09-473C-B0B8-3DD78957D242Q46715164-463D7A3D-3F2F-4043-BE32-6926C9BCE769Q47554182-66A8FC50-F853-4DFF-B843-6C7917C291F9Q52617852-B1956924-2729-4540-8EEA-69A87CB21A3EQ53834997-7BFB5EE5-14EE-41B8-B229-56DD7275C07DQ61799756-D8BDDA4D-8D78-45EC-810D-5B27F39FB42BQ90105135-7DF5B727-7C09-4301-8497-4EDB420374AEQ90178623-773D9844-FCE6-4C40-8DE5-8F8A5D10E2B5Q90832472-0E20F6CA-E091-46F3-8608-DF5FACB19983Q90846895-7D7D49E1-3FB9-4B3F-8906-BCFB0650DF72Q91464771-18D4EDF5-180F-40F2-AB9E-C85EF6D7FE68Q91638303-F0F25F9B-699A-465B-A89B-606D1E92C613Q92235239-FC3ADCC7-E0A2-45C0-A5A2-9E912B902242Q92440306-4B10B14D-4D50-4BB3-BCD5-39D13B4F4456Q92471685-7DA5B430-0EFF-4DDC-A227-9461237D4588Q93011916-1499F5D1-6D80-4AC1-8855-CC7E67B8C916Q93187763-2D3D5C90-0F20-48CD-975E-081541B18B37Q93348253-36131057-6445-4A9E-A4F9-755716D6F326
P50
description
researcher
@en
name
David V Glidden
@en
type
label
David V Glidden
@en
prefLabel
David V Glidden
@en
P31
P496
0000-0001-5888-1419